Trials / Completed
CompletedNCT00608803
Phase 1 Study of ZIO-201-T in Combination With Doxorubicin in Solid Tumors
A Phase I Study of ZIO-201-T in Combination With Doxorubicin in Subjects With Advanced, Refractory Solid Tumors for Which no Standard Therapy Exists and for Whom Treatment With Doxorubicin is Considered Medically Acceptable
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Alaunos Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study of safety of ZIO-201-T in combination with doxorubicin in the treatment of advanced cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ZIO-201-T and doxorubicin | ZIO-201-T given for 3 consecutive days every 3 weeks. Doxorubicin is given once every 3 weeks. This is a dose escalation arm. |
Timeline
- Start date
- 2008-01-01
- Primary completion
- 2009-01-01
- Completion
- 2009-01-01
- First posted
- 2008-02-06
- Last updated
- 2009-09-17
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00608803. Inclusion in this directory is not an endorsement.